EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
about
Efficacy and safety at 24 weeks of daily clinical use of tofacitinib in patients with rheumatoid arthritis.Patients' conceptions of their own influence on good treatment response to biological therapy in chronic inflammatory arthritis.Patient-reported outcomes from a phase 3 study of baricitinib versus placebo or adalimumab in rheumatoid arthritis: secondary analyses from the RA-BEAM study.Triple DMARD treatment in early rheumatoid arthritis modulates synovial T cell activation and plasmablast/plasma cell differentiation pathways.Filgotinib for the treatment of rheumatoid arthritis.Thyroid Autoimmunity and Function after Treatment with Biological Antirheumatic Agents in Rheumatoid Arthritis.Practical Management of Respiratory Comorbidities in Patients with Rheumatoid Arthritis.Opportunities and challenges in the immunological therapy of pediatric malignancy: a concise snapshot.Pharmacokinetics, efficacy and safety of the rituximab biosimilar CT-P10.Efficacy of baricitinib in the treatment of rheumatoid arthritis.Patient access to reimbursed biological disease-modifying antirheumatic drugs in the European region.Managing rheumatic and musculoskeletal diseases - past, present and future.Rheumatoid arthritis patients' motivations for accepting or resisting disease-modifying antirheumatic drug treatment regimens.CT-P13 in the treatment of rheumatoid arthritis.Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.Abatacept: A Review in Rheumatoid Arthritis.Clinical utility of therapeutic drug monitoring in biological disease modifying anti-rheumatic drug treatment of rheumatic disorders: a systematic narrative review.Rheumatoid arthritis: The benefits of early treatment after decades.Ras Signaling Inhibitors Attenuate Disease in Adjuvant-Induced Arthritis via Targeting Pathogenic Antigen-Specific Th17-Type Cells.Muscle Weakness in Rheumatoid Arthritis: The Role of Ca2+ and Free Radical Signaling.Sustained remission in rheumatoid arthritis: latest evidence and clinical considerations.Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria.Opportunities and challenges in rheumatology research in Central Europe.Further Treatment Intensification in Undifferentiated and Rheumatoid Arthritis Patients Already in Low Disease Activity has Limited Benefit towards Physical Functioning.Changes in clinical disease activity are weakly linked to changes in MRI inflammation on treat-to-target escalation of therapy in rheumatoid arthritis.Tofacitinib: A Review in Rheumatoid Arthritis.Tocilizumab: A Review in Rheumatoid Arthritis.Glucocorticoid management in rheumatoid arthritis: morning or night low dose?Certolizumab Pegol in the Treatment of Psoriasis and Psoriatic Arthritis: Preliminary Real-Life Data.Chinese Registry of rheumatoid arthritis (CREDIT): II. prevalence and risk factors of major comorbidities in Chinese patients with rheumatoid arthritis.Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis.Diagnostic delays in rheumatic diseases with associated arthritis.Practical Management of Cardiovascular Comorbidities in Rheumatoid Arthritis.The role of ultrasonography in monitoring long-standing rheumatoid arthritis: a pilot study.A Phase III Study Evaluating Continuation, Tapering, and Withdrawal of Certolizumab Pegol After One Year of Therapy in Patients With Early Rheumatoid Arthritis.REDOSER project: optimising biological therapy dose for rheumatoid arthritis and spondyloarthritis patients.Single-Arm Study of Etanercept in Adult Patients with Moderate to Severe Rheumatoid Arthritis Who Failed Adalimumab Treatment.Diagnosis and Treatment of Inflammatory Joint Disease.Treatment Persistence and Healthcare Costs Among Patients with Rheumatoid Arthritis Changing Biologics in the USA.
P2860
Q33638048-15BE9DCB-C6BB-4909-AA0C-5626FAFEA3D2Q33865344-265004C6-773D-4C4E-B40B-2B6E76C856F4Q38372369-1C42C83C-BE6C-4A6F-8250-FF527D2CA384Q38597826-CE41DAEC-D98B-45F6-A8EB-E3787BEB6683Q38609755-6A64B9EE-61A8-4329-AE80-4049B1806BF1Q38616745-411E90BD-5A1E-4228-B95B-0342565ACBB9Q38642378-49DCE704-7AD3-4FEF-A22C-CD59B706148BQ38643300-CD6CB21B-799B-4084-A42C-9E22EFEFC039Q38647397-318A7C84-66C3-40D9-9F32-9A16B27F51C1Q38652849-F65FEB84-9670-47F5-B375-76160E0292A5Q38663329-74DD60C1-D647-44B3-888C-D2E47EDBA6E5Q38670973-2E4EBF9D-8201-46D0-84EB-744631A38B43Q38675559-5DEBB941-127D-495E-A0E9-FA1FE888816EQ38676104-09D7DB87-29D4-4775-A4B1-123981C378B9Q38690324-4BEABB95-EC5B-4C4D-BC6E-A1D3C938D358Q38745066-3451240D-7AF4-465B-9548-A76E9195C296Q39368606-AF6774F7-90C4-4BC2-9F0A-98982A90E748Q39420995-D06AE17F-E342-4DFC-8290-16722A7EEBB0Q40141482-D7852940-0DD3-4F24-8966-BB019FC6751FQ40954990-802659E5-F90F-4F53-BA10-A45A978EE9F7Q41688477-197FAD06-9E31-4A1C-8047-7EC680394682Q42273153-5D528407-F479-4F77-9003-7FAEB9282B03Q42285413-672F7290-A7FB-4031-87A1-1DF5241B036AQ42353372-F3495076-EF81-4C4D-B59A-ACAC75612712Q42368157-8807B646-E40B-4AE1-839A-661A2A497055Q42634337-6A61ABB7-25C3-4192-BE8A-33A6B61CD40BQ43280727-4586CEFB-0E8B-42C1-B971-660DC4C59D0AQ43280791-B67B5B00-841E-49BB-AA64-BFD61FCB929CQ44522776-7A6D17AA-DDDB-498A-A09C-9FB69EBFF637Q45774045-82F392F2-8FA1-4DBE-A887-AC4AD232CD34Q45796102-C0141C24-DDDE-4BCA-8580-C756A4419352Q46008507-131A5078-D5E1-4705-972A-C2EE1C8367B9Q46088405-DD22F28C-0248-440F-9042-58B3CF920380Q46089585-EAAD38EC-3CDE-4BB2-B95D-3FEA65A7C89DQ46742113-9472677C-3816-4E5B-AA7C-53BBE35ED08DQ46930972-B885F6FD-ACE5-4CAD-B108-C57CEFCBF599Q47097484-0B1D29A0-3E67-4073-A70F-E79329174434Q47107623-B91FA6BB-274E-470E-B8B9-6CA47A2163B6Q47130216-E30B7379-427F-4FE3-B44C-9B79EC26D51FQ47131401-E5472594-7E41-4B4E-A003-8300F7C09965
P2860
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
EULAR recommendations for the ...... irheumatic drugs: 2016 update.
@en
EULAR recommendations for the ...... irheumatic drugs: 2016 update.
@en-gb
type
label
EULAR recommendations for the ...... irheumatic drugs: 2016 update.
@en
EULAR recommendations for the ...... irheumatic drugs: 2016 update.
@en-gb
prefLabel
EULAR recommendations for the ...... irheumatic drugs: 2016 update.
@en
EULAR recommendations for the ...... irheumatic drugs: 2016 update.
@en-gb
P2093
P50
P1154
2-s2.0-85019702082
P1476
EULAR recommendations for the ...... irheumatic drugs: 2016 update.
@en
P2093
Andrea Rubbert-Roth
Axel Finckh
Bernard Combe
Chris D Buckley
Christophe Richez
Daniel Aletaha
Dmitry Karateev
Eduardo Mysler
Gerd Burmester
Gyula Poór
P304
P356
10.1136/ANNRHEUMDIS-2016-210715
P407
P50
P5530
P577
2017-03-06T00:00:00Z
P6179
1084224206